Company Profile
Black Diamond Therapeutics Stock Price, News & Analysis
- Ticker:
- BDTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.92 USD (+7.26%)
Close
Last updated: August 6, 2026
125M USD
Market cap
Why the stock is moving
Following the latest company update, “Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update”, BDTX closed up 7.26% at $1.92 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Mutation-Family Precision Oncology
Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule.
Silevertinib
Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to address with mutation-specific drugs.
Frontline Lung Cancer
The Phase 2 non-small cell lung cancer program is evaluating response durability, progression-free survival and dose selection in patients with newly diagnosed EGFR-mutated disease.
Glioblastoma
A separate Phase 2 study evaluates silevertinib in newly diagnosed EGFRvIII-positive glioblastoma, using the candidate's brain penetration to address a distinct EGFR-driven tumor.
Future catalysts
Phase 2 frontline EGFR-mutated NSCLC data, including preliminary duration-of-response and progression-free-survival results, at ASCO 2026.
Recent news
- 01
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Source: Black Diamond Therapeutics
- 02
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Source: Black Diamond Therapeutics
- 03
- 04
- 05
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Black Diamond Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Black Diamond Therapeutics (BDTX)?
Black Diamond Therapeutics (BDTX) most recently closed at 1.92 USD, a +7.26% move versus the previous session.
What is the market cap of Black Diamond Therapeutics (BDTX)?
Black Diamond Therapeutics currently has a market capitalization of 125M USD on BioPharmSignal.
What does Black Diamond Therapeutics do?
Mutation-Family Precision Oncology Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule. Silevertinib Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to address with...
On which exchange is BDTX stock listed?
Black Diamond Therapeutics (BDTX) is associated with NASDAQ, United States, Biopharma.
What is silevertinib?
Silevertinib Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to address with mutation-specific drugs.
Which conditions is Black Diamond Therapeutics targeting with silevertinib?
Black Diamond Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Black Diamond Therapeutics describe recent progress with silevertinib?
Phase 2 frontline EGFR-mutated NSCLC data, including preliminary duration-of-response and progression-free-survival results, at ASCO 2026.
What is Mutation-Family?
Mutation-Family Precision Oncology Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule.